2 news items
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
MYGN
23 May 24
is currently available for use in research studies pursued jointly by Myriad and academic or pharmaceutical investigators and is expected to launch
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
MYGN
21 Mar 24
and academic or pharmaceutical investigators. "The sensitivity and detection limit achieved with Precise MRD allows it to perform across a wide range
- Prev
- 1
- Next